Table 1 First-line treatment decisions
n, % | EGFR Mut+ n = 334 | EGFR Mut- n = 2481 | EGFR Mx n = 131 | Total N = 2946 |
|---|---|---|---|---|
Agent | ||||
Carboplatin | 74 (22.2) | 1203 (48.5) | 62 (47.3) | 1339 (45.5) |
Cisplatin | 60 (18.0) | 897 (36.2) | 43 (32.8) | 1000 (33.9) |
Pemetrexed | 39 (11.7) | 754 (30.4) | 38 (29.0) | 831 (28.2) |
Gemcitabine | 37 (11.1) | 603 (24.3) | 36 (27.5) | 676 (22.9) |
Vinorelbine | 43 (12.9) | 586 (23.6) | 41 (31.3) | 670 (22.7) |
Paclitaxel | 21 (6.3) | 284 (11.4) | 8 (6.1) | 313 (10.6) |
Gefitinib | 177 (53.0) | 6 (0.2) | 0 | 183 (6.2) |
Bevacizumab | 18 (5.4) | 142 (5.7) | 1 (0.8) | 161 (5.5) |
Docetaxel | 3 (0.9) | 97 (3.9) | 1 (0.8) | 101 (3.4) |
Etoposide | 1 (0.3) | 76 (3.1) | 3 (2.3) | 80 (2.7) |
Erlotinib | 12 (3.6) | 46 (1.9) | 3 (2.3) | 61 (2.1) |
Other | 0 | 19 (0.8) | 1 (0.8) | 20 (0.7) |
Cetuximab | 0 | 3 (0.1) | 0 | 3 (0.1) |
Type of treatment | ||||
Combination chemotherapy | 117 (35.0) | 1947 (78.5) | 103 (78.6) | 2167 (73.6) |
Monochemotherapya | 10 (3.0) | 319 (12.9) | 23 (17.6) | 352 (11.9) |
TKI | 189 (56.6) | 49 (2.0) | 3 (2.3) | 241 (8.2) |
Chemotherapy + bevacizumab and/or cetuximab | 18 (5.4) | 141 (5.7) | 1 (0.8) | 160 (5.4) |
Not classifiableb | 0 | 19 (0.8) | 1 (0.8) | 20 (0.7) |
Other | 0 | 6 (0.2) | 0 | 6 (0.2) |